{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:46:43Z","timestamp":1792039603671,"version":"4.4.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.lungcan.2026.109642","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:07:21Z","timestamp":1791040041000},"page":"109642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Trial-specific absolute disease-free survival effects of postoperative PD-1\/PD-L1 blockade after complete resection of NSCLC: A systematic review"],"prefix":"10.1016","volume":"221","author":[{"given":"Zhiheng","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhou","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109642_b0005","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2026.109642_b0010","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1200\/JCO-24-01681","article-title":"Five-year survival outcomes with atezolizumab after chemotherapy in resected stage IB-IIIA non-small cell lung cancer (IMpower010): an open-label, randomized, phase III trial","volume":"43","author":"Felip","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109642_b0015","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O'Brien","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2026.109642_b0020","unstructured":"European Medicines Agency. Keytruda-H-C-003820-II-0121: EPAR - assessment report - variation. EMA\/451876\/2023. 14 September 2023. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/keytruda-h-c-003820-ii-0121-epar-assessment-report-variation_en.pdf. Accessed 11 August 2026."},{"key":"10.1016\/j.lungcan.2026.109642_b0025","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1200\/JCO-25-01828","article-title":"Adjuvant durvalumab in completely resected early-stage non-small cell lung cancer","volume":"44","author":"Goss","year":"2026","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109642_b0030","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2026.8992","article-title":"Adjuvant nivolumab vs observation in resected non-small cell lung cancer: a randomized clinical trial","volume":"336","author":"Chaft","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.lungcan.2026.109642_b0035","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2014.55.2208","article-title":"Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis","volume":"32","author":"Uno","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109642_b0040","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-025-01250-9","article-title":"How hazard ratios can mislead and why it matters in practice","volume":"40","author":"Dumas","year":"2025","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.lungcan.2026.109642_b0045","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1056\/NEJMc1716612","article-title":"Hazards of hazard ratios\u2014deviations from model assumptions in immunotherapy","volume":"378","author":"Alexander","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109642_b0050","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/annonc\/mdy075","article-title":"Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer","volume":"29","author":"Liang","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109642_b0055","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/annonc\/mdy462","article-title":"Interpretation of time-to-event outcomes in randomized trials: an online randomized experiment","volume":"30","author":"Weir","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109642_b0060","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med. Res. Method."},{"key":"10.1016\/j.lungcan.2026.109642_b0065","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1002\/sim.6556","article-title":"Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data","volume":"34","author":"Wei","year":"2015","journal-title":"Stat. Med."},{"key":"10.1016\/j.lungcan.2026.109642_b0070","article-title":"Adjuvant immunotherapy improves survival in completely resected stage IB\u2013III non-small-cell lung cancer: a systematic review and meta-analysis","volume":"15","author":"Huang","year":"2025","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109642_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105759","article-title":"Immunotherapy for resectable non-small-cell lung cancer: neoadjuvant\/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses","volume":"10","author":"Rossi","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.lungcan.2026.109642_b0080","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.lungcan.2026.109642_b0085","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13643-020-01542-z","article-title":"PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews","volume":"10","author":"Rethlefsen","year":"2021","journal-title":"Syst. Rev."},{"key":"10.1016\/j.lungcan.2026.109642_b0090","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.lungcan.2026.109642_b0095","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan\u2013Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med. Res. Method."},{"key":"10.1016\/j.lungcan.2026.109642_b0100","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan\u2013Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med. Res. Method."},{"key":"10.1016\/j.lungcan.2026.109642_b0105","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jval.2021.12.004","article-title":"Validating restricted mean survival time estimates from reconstructed Kaplan\u2013Meier data against original trial individual patient data from trials conducted by the Canadian Cancer Trials Group","volume":"25","author":"Everest","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.lungcan.2026.109642_b0110","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12874-015-0091-1","article-title":"Hartung-Knapp-Sidik-Jonkman approach and its modification for random-effects meta-analysis with few studies","volume":"15","author":"R\u00f6ver","year":"2015","journal-title":"BMC Med. Res. Method."},{"key":"10.1016\/j.lungcan.2026.109642_b0115","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-073725","article-title":"CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials","volume":"381","author":"Junqueira","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.lungcan.2026.109642_b0120","article-title":"PRISMA Harms Group. PRISMA harms checklist: improving harms reporting in systematic reviews","volume":"352","author":"Zorzela","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.lungcan.2026.109642_b0125","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Savovi\u0107 J, Page MJ, Sterne JAC, editors. Revised Cochrane risk-of-bias tool for randomized trials (RoB 2). Version 22 August 2019. Cochrane; 2019.","DOI":"10.1002\/9781119536604.ch8"},{"key":"10.1016\/j.lungcan.2026.109642_b0130","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076754","article-title":"ROB-ME: a tool for assessing risk of bias due to missing evidence in systematic reviews with meta-analysis","volume":"383","author":"Page","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.lungcan.2026.109642_b0135","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jclinepi.2017.05.006","article-title":"The GRADE Working Group clarifies the construct of certainty of evidence","volume":"87","author":"Hultcrantz","year":"2017","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.lungcan.2026.109642_b0140","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.7326\/ANNALS-25-00548","article-title":"GRADE certainty ratings: thresholds rather than categories of contextualization (GRADE Guidance 41)","volume":"178","author":"Hultcrantz","year":"2025","journal-title":"Ann. Intern. Med."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226007038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226007038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:09:16Z","timestamp":1792037356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226007038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":28,"alternative-id":["S0169500226007038"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109642","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trial-specific absolute disease-free survival effects of postoperative PD-1\/PD-L1 blockade after complete resection of NSCLC: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109642","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109642"}}